Revista Colombiana de Reumatología (English Edition)最新文献

{"title":"Effectiveness of glyceryl trinitrate patch use in secondary Raynaud's phenomenon","authors":"Silvia Méndez-Flores ,&nbsp;Dulce María Carrillo-Córdova ,&nbsp;Rafael López-Loya ,&nbsp;Bruno Estañol-Vidal","doi":"10.1016/j.rcreue.2024.12.005","DOIUrl":"10.1016/j.rcreue.2024.12.005","url":null,"abstract":"<div><h3>Introduction/objective</h3><div>Secondary Raynaud's phenomenon is one of the primary cutaneous manifestations of various rheumatological diseases, which can significantly impact quality of life and whose systemic treatment can lead to several adverse effects. Therefore, this study was conducted to assess the effectiveness of glyceryl trinitrate (in transdermal patch form) in patients with secondary Raynaud's phenomenon (SRP), evaluated through vascular flow photoplethysmography.</div></div><div><h3>Materials and methods</h3><div>A comparative, analytical, open-label, non-randomized study was conducted to evaluate the efficacy of 4.5 mg of glyceryl trinitrate in a transdermal patch placed on the proximal region of one hand in patients diagnosed with SRP compared to the untreated contralateral hand. To determine the primary outcome, vascular flow photoplethysmography assessment was performed 30 days after daily patch use. Secondary results were obtained using an infrared thermometer to measure local temperature in both hands before patch application, 30 min after patch use, and at the end of the follow-up period. Additionally, various questionnaires, including the Visual Analogue Scale for pain, Raynaud's Condition Score (RCS), and Dermatology Quality of Life Index (DLQI), were administered on the first and last days of the study.</div></div><div><h3>Results</h3><div>Sixteen patients, all female, with a median age of 54 years, were included. Regarding the rheumatological diseases associated with secondary Raynaud's phenomenon, twelve patients (75% of the sample) were associated with systemic sclerosis, three patients (19%) with lupus erythematosus, and one (6%) with mixed connective tissue disease (MCTD). There was a significant increase in peripheral blood flow after 30 days of treatment with 4.5 mg of glyceryl trinitrate every 24 h, along with improvement in clinical symptom and quality of life questionnaires.</div></div><div><h3>Conclusions</h3><div>This study supports the use of low-dose glyceryl trinitrate via transdermal patches to improve vascular flows, translating into short-term clinical symptom improvement associated with SRP.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 2","pages":"Pages 130-136"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk predictors for adverse COVID-19 outcomes in Latin American patients with autoimmune rheumatic diseases: A multicentre study in Ecuador and Mexico","authors":"Santiago Guzmán-García ,&nbsp;Goethe Sacoto-Flores ,&nbsp;Johanna Román-Bermeo ,&nbsp;Fabiana Samaniego-Burneo ,&nbsp;María Ochoa ,&nbsp;Franklin Uguña-Sari ,&nbsp;Gladis Molina-Alvarado ,&nbsp;Luis M. Amezcua-Guerra","doi":"10.1016/j.rcreue.2025.04.004","DOIUrl":"10.1016/j.rcreue.2025.04.004","url":null,"abstract":"<div><h3>Introduction/objectives</h3><div>The understanding of COVID-19 progression among patients with autoimmune rheumatic diseases (SARDs) in Latin America remains limited. This study aimed to identify risk predictors associated with poor outcomes of COVID-19 in patients with SARDs.</div></div><div><h3>Materials and methods</h3><div>An observational multicentre study including patients with SARDs from Ecuador and Mexico.</div></div><div><h3>Results</h3><div>A total of 103 patients (78% women), aged 52.5<!--> <!-->±<!--> <!-->17.7 years, were enrolled. The most prevalent SARDs were rheumatoid arthritis (59%) and systemic lupus erythematosus (SLE; 24%). Severe COVID-19 was observed in 28% of patients at admission, 43% experienced complications during follow-up, and 8% ultimately died. Mortality rates were highest in patients with antiphospholipid syndrome (27%) or SLE (20%). Poor prognostic factors included acute respiratory distress syndrome (odds ratio [OR]<!--> <!-->=<!--> <!-->17.07), severe COVID-19 at admission (OR<!--> <!-->=<!--> <!-->11.45), and presence of SLE (OR<!--> <!-->=<!--> <!-->4.62). In multivariate analysis, SLE emerged as the sole predictor of mortality (OR<!--> <!-->=<!--> <!-->15.61).</div></div><div><h3>Conclusions</h3><div>Patients with SARDs in Latin America face significant risks of adverse COVID-19 outcomes, with SLE being a major risk factor for mortality.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 2","pages":"Pages 152-158"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143916896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential biomarkers present in the urine of patients with systemic lupus erythematosus: An exploratory study in Colombian patients","authors":"Yeimy Paola Trujillo ,&nbsp;Alfonso Kerguelen ,&nbsp;Sandra Amado ,&nbsp;Santiago Bernal-Macías ,&nbsp;Daniel Gerardo Fernández-Ávila ,&nbsp;Alfonso Barreto-Prieto ,&nbsp;Luz-Stella Rodríguez","doi":"10.1016/j.rcreue.2024.12.006","DOIUrl":"10.1016/j.rcreue.2024.12.006","url":null,"abstract":"<div><h3>Objective</h3><div>To describe the urinary levels of molecules related to removing apoptotic cells and triggering inflammation, as well as cytokines involved in Colombian patients with systemic lupus erythematosus without and with lupus nephritis compared to healthy controls.</div></div><div><h3>Materials and methods</h3><div>Urine samples were taken from three groups of patients: healthy controls (n = 7), patients with systemic lupus erythematosus without lupus nephritis (n = 7), and patients with lupus and lupus nephritis (n = 4). The urine sample was collected and concentrated by ultrafiltration. A western blot evaluated HMGB1, HISTONE H3, CALRETICULIN (CRT), ANNEXIN A1 and CD46, CX3CL1 by ELISA and cytokines such as IL-8, IL-6, IL-12p70, TNF-α, and IL-1β by flow cytometry.</div></div><div><h3>Results</h3><div>Histone H3 was detected in two patients, one with systemic lupus erythematosus without lupus nephritis and one with systemic lupus erythematosus and lupus nephritis. The detected band suggests a post-translational modification. There were no differences between the levels of HMGB1 and CX3CL1 in the study groups. CD46, ANNEXIN A1, and CRT were not detected in our samples. When evaluating cytokines in urine, an increase in IL-8 was observed in the group of patients with systemic lupus erythematosus without nephritis compared to controls. For IL-6, an increase was found among patients without lupus nephritis when compared with patients with lupus nephritis. No differences were found between the urinary levels of the other cytokines evaluated (IL-12p70, TNF-α, IL-1β, and IL-10).</div></div><div><h3>Conclusion</h3><div>Urinary histone H3 and IL-8 levels may be interesting molecules to be evaluated in more patients with systemic lupus erythematosus, while HMGB1 and CX3CL1 are not useful. Further evaluation of patients is required to confirm these findings.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 2","pages":"Pages 159-167"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Common variable immune deficiency complicating proliferative lupus nephropathy: A diagnostic and therapeutic challenge","authors":"Lamia Bengherbia,&nbsp;Said Taharboucht,&nbsp;Oussama Souas,&nbsp;Hassina Chicha,&nbsp;Ahcene Chibane","doi":"10.1016/j.rcreue.2025.04.005","DOIUrl":"10.1016/j.rcreue.2025.04.005","url":null,"abstract":"<div><h3>Introduction</h3><div>Common variable immunodeficiency (CVID) is a rare condition characterized by a constitutional humoral immune deficiency. Its association with systemic lupus is extremely rare.</div></div><div><h3>Case presentation</h3><div>In this case report, we present a 21-year-old woman with a history of Hashimoto's thyroiditis, who, following the onset of nephrotic syndrome revealing her lupus disease, subsequently developed clinical and laboratory features consistent with CVID, alongside recurrent lupus flares. Her initial therapeutic management was intricate, ultimately resulting in stable remission achieved through monthly immunoglobulin infusions.</div></div><div><h3>Conclusion</h3><div>This case illustrates the diagnostic and therapeutic difficulty of lupus disease and a common variable immune deficiency.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 2","pages":"Pages 168-172"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143916883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoimmune haemolytic anaemia due to cold agglutinins associated with systemic lupus erythematosus. Case presentation and literature review","authors":"Jaime Alberto Coral Enríquez ,&nbsp;Victoria Eugenia Cajas Bravo","doi":"10.1016/j.rcreue.2024.12.004","DOIUrl":"10.1016/j.rcreue.2024.12.004","url":null,"abstract":"<div><h3>Introduction</h3><div>Cold agglutinin autoimmune haemolytic anaemia (AIHA) secondary to systemic lupus erythematosus (SLE) is a rare manifestation. There are no cohorts or case series that allow us to evaluate the characteristics of this group of patients.</div></div><div><h3>Objective</h3><div>To describe the clinical and serological characteristics of patients with systemic lupus erythematosus (SLE) and cold agglutinin hemolytic anemia.</div></div><div><h3>Materials and methods</h3><div>We present two cases with SLE that debuted with cold agglutinin AHAI, their clinical and immunological profile and response to immunosuppressive treatment.</div></div><div><h3>Results</h3><div>Eleven cases reported in the literature from 1950 to 2023 are described.</div></div><div><h3>Conclusion</h3><div>Cold agglutinin AIHA secondary to SLE is rare, with unclear clinical features compared to idiopathic forms and usually not associated with manifestations or serious organic involvement.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 2","pages":"Pages 173-179"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associated factors of antiphospholipid syndrome. When do we need antiphospholipid antibodies?","authors":"Jaime Andrés Escobar Sáenz ,&nbsp;Oscar Muñoz Velandia ,&nbsp;Paula Ruiz Talero ,&nbsp;Daniel Fernández Ávila","doi":"10.1016/j.rcreue.2025.02.004","DOIUrl":"10.1016/j.rcreue.2025.02.004","url":null,"abstract":"<div><h3>Introduction</h3><div>In clinical practice, there is no specific recommendation on when to take samples in case of clinical suspicion of antiphospholipid syndrome, only a list of factors that generate APS risk, without adequately quantifying the weight of each of these factors.</div></div><div><h3>Materials and methods</h3><div>Analytical observational case-control study, nested in a retrospective cohort of patients with venous or arterial thrombosis in whom antiphospholipid syndrome was clinically suspected. Patients with a confirmed diagnosis of antiphospholipid syndrome according to the Sapporo criteria or triple positive initial result (cases) are compared with patients negative for APS (controls). The association between the diagnosis of APS and different clinical and paraclinical factors was evaluated.</div></div><div><h3>Results</h3><div>68 patients were included (72% women, 41.2% with deep venous thromboembolism and 29.4% with pulmonary embolism). In 18 SAF was confirmed. There were no significant differences in age in patients with and without confirmation of the diagnosis (44.0±17.9 vs. 51.2±14.9, p = 0.069). In the multivariate analysis, a significant and independent association was found between having APS and rheumatic disease (OR 12.1, p = 0.02), PTT prolongation (OR 17.6, p = 0.014), platelet count &lt; 150000 (OR 18.6, p = 0.008), and a history of previous thrombosis events (OR: 6.1 for each event, p = 0.027).</div></div><div><h3>Conclusions</h3><div>In patients with arterial or venous thrombosis, there is a greater possibility of confirming antiphospholipid syndrome if there is a history of rheumatic disease, prolongation of PTT to more than 5 seconds, thrombocytopenia, and previous events of thrombotic disease. In these patients it is advisable to search for APS, in order to prevent new events.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 2","pages":"Pages 137-144"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143916881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge of medications and understanding of Mexican patients regarding the non-medical switch from originator to its biosimilar in inflammatory arthritis","authors":"Carlos Andrés Díaz-Garza ,&nbsp;Alejandro Garza-Alpirez ,&nbsp;David Vega-Morales ,&nbsp;Deshiré Alpizar-Rodríguez ,&nbsp;Berenice Carrillo-Haro","doi":"10.1016/j.rcreue.2025.04.002","DOIUrl":"10.1016/j.rcreue.2025.04.002","url":null,"abstract":"<div><h3>Introduction/Objective</h3><div>Our aim was to know patient's understanding and concerns about biosimilars, switching, and non-medical switch in Mexican population.</div></div><div><h3>Materials and methods</h3><div>A cross-sectional social media survey via the Mexican Foundation for Rheumatic Patients (FUMERAC) was conducted from November 2020 to January 2021. Patients were eligible if they were &gt;18 years of age with any inflammatory rheumatic condition.</div></div><div><h3>Results</h3><div>A total of 165 participants completed the survey. The most frequent diagnoses were Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis. Disease-modifying antirheumatic drugs as monotherapy was the most common treatment. Prior or current users of biologics were reported. Most participants had never heard the term biosimilar. Some would accept the change from an originator to its biosimilar and few would take legal measure or file a complaint if a non-medical switch were to happen. Patients had concerns on treatment effectiveness, adverse effects, reason for change, treatment duration, and other patient's experience.</div></div><div><h3>Conclusion</h3><div>In Mexico, the concept of biosimilars is barely known. Most patients would not take any measure if they were changed from an originator to its biosimilar.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 2","pages":"Pages 105-109"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of simple hematological parameters with disease activity and damage indices among Egyptian patients with systemic lupus erythematosus","authors":"Hanan H. Ahmed ,&nbsp;Hebatallah S. Farag ,&nbsp;Nesreen Sobhy","doi":"10.1016/j.rcreue.2025.04.003","DOIUrl":"10.1016/j.rcreue.2025.04.003","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the correlation of different hematological parameters in lupus patients with SLE disease activity index (SLEDAI), the Systemic Lupus International Collaboration Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI), and some laboratory data related to kidney functions in active patients with nephritis.</div></div><div><h3>Material and methods</h3><div>80 inactive SLE patients (SLEDAI score<!--> <!-->&lt;<!--> <!-->10 points), and 80 active patients (SLEDAI<!--> <!-->≥<!--> <!-->10 points) were enrolled in this study. All patients underwent full medical history taking, clinical evaluation including calculation of SLEDAI and SLICC/ACR DI scores, and laboratory investigations including complete blood count. The two groups were compared regarding different disease parameters. Correlations of some hematological parameters with SLEDAI, SLICC/ACR DI scores and some laboratory data related to kidney function in patients with nephritis were made.</div></div><div><h3>Results</h3><div>The active group showed statistically significantly higher mean NLR (<em>P</em> <!-->=<!--> <!-->0.000), NC3R (<em>P</em> <!-->=<!--> <!-->0.000), MLR (<em>P</em> <!-->=<!--> <!-->0.000), PLR (<em>P</em> <!-->=<!--> <!-->0.000), and RDW (<em>P</em> <!-->=<!--> <!-->0.001), and statistically significantly lower mean MPV (<em>P</em> <!-->=<!--> <!-->0.002). The mean MLR (<em>P</em> <!-->=<!--> <!-->0.018) and PLR (<em>P</em> <!-->=<!--> <!-->0.005) were statistically significantly higher in the active patients with nephritis. For both groups, there were no significant correlations between studied parameters and SLEDAI or SLICC/ACR DI, except with NC3R values in the active group which were associated with SLEDAI (<em>r</em> <!-->=<!--> <!-->.221, <em>P</em> <!-->=<!--> <!-->0.049).</div></div><div><h3>Conclusion</h3><div>The hematological parameters in SLE have promising potential clinical application as a novel activity marker, especially in patients with nephritis.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 2","pages":"Pages 145-151"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143916882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ABC of lupus nephritis","authors":"José A. Gómez-Puerta","doi":"10.1016/j.rcreue.2025.03.003","DOIUrl":"10.1016/j.rcreue.2025.03.003","url":null,"abstract":"","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 2","pages":"Pages 103-104"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sociodemographic, clinical, and biochemical characteristics of patients who presented with and without lupus nephritis in a cohort of Mexican patients with systemic lupus erythematosus in a referral centre","authors":"Fabiola Pazos-Pérez ,&nbsp;Aida Martínez-Badajoz ,&nbsp;Francisco M. Bravo-Rojas ,&nbsp;Estafanía Garduño-Hernández ,&nbsp;María I. Gil-Arredondo ,&nbsp;Rocío Catana-Hernández ,&nbsp;Mario C. Ocampo-Torres ,&nbsp;Juan C. Hernández-Rivera","doi":"10.1016/j.rcreue.2025.02.005","DOIUrl":"10.1016/j.rcreue.2025.02.005","url":null,"abstract":"<div><h3>Introduction</h3><div>Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease that presents great clinical heterogeneity, so that up to 60% of patients may develop lupus nephropathy (LN).</div></div><div><h3>Objective</h3><div>To identify demographic, clinical, and biochemical characteristics of patients presenting with and without lupus nephritis at the time of SLE diagnosis in a cohort of Mexican patients</div></div><div><h3>Materials and methods</h3><div>This is a cross-sectional, analytical, and single-centre study. Frequencies and percentages were used for categorical variables and the comparison was made with Pearson's Chi2 statistical test or Fisher's exact test. For the quantitative variables, their distribution was calculated and according to this, Student's t was used in case of normal distribution and Mann-Whitney U for those with free distribution.</div></div><div><h3>Results</h3><div>Of 160 patients, 79 (49.37%) had LN. These individuals had a higher prevalence of serositis (14.3 vs. 8.1%, p = 0.048) and arterial hypertension (40.50% vs. 24.6%, p = 0.033), while those without LN had a higher prevalence of rheumatoid arthritis and joint disease (6 vs. 1%, p = 0.052), allergies (43.2 vs. 20.25%, p = 0.002), infections (23.45 vs. 10%, p = 0.020), and lower levels of C3 (52.25±28.7 vs. 74.6±32.2 mg/dl, p &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>The characteristics described in our cohort are like those presented in other Latino and Asian series. However, the presence of concomitant infections at the time of SLE diagnosis has not been described and should be considered for future research.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 2","pages":"Pages 110-117"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}